Abstract:Among the numerous endogenous promoters of angiogenesis, vascular endothelia growth factor (VEGF) plays a leading role in angiogenesis, which has huge impact on proliferation, survival, migration and permeability of tumor cells. VEGF signal system also becomes remarkable anticancer targets, including VEGF, vascular endothelia growth factor receptor (VEGFR), and VEGF downstream signal pathways. So far, there has been many clinical or approved anticancer drugs that directly or indireactly interfere with VEGF signal system applied in the treatment of various tumors and other diseases associated with pathological angiogenesis. Various kinds of antiangiogenic agents which inhibit VEGF and VEGFR have been developed and discovered gradually, including antibodies, ribozymes and small molecule inhibitors. Meanwhile, the investigation into antiangiogenic agents which block certain signal proteins of VEGF downstream signal pathways attracts the attention of medicinal chemists and enriches the application of antiangiogenic agents. This review will interpret the mysterious VEGF signal system from its molecular structure and probe to the mechanism of the combination of VEGF and its receptors. Furthermore, the detail of VEGF signal pathways will be introduced comprehensively and methodically. In addition, some up-to-date clinical or approved anticancer agents will be clearly tabulated. The binding modes of different kinase inhibitors will be used to explain the SAR of the small molecule inhibitors. Finally, in order to make the readers master VEGF signal system completely, some novel targets and inhibitors which block the downstream signal pathways of VEGF are plainly stated.

The Impact of VEGF on Cancer Metastasis and Systemic Disease.

Tumor-derived Vascular Endothelial Growth Factor (Vegf)-a Facilitates Tumor Metastasis Through the VEGF-VEGFR1 Signaling Pathway.

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Lymphangiogenesis in cancers:a therapy target

VEGF-C, VEGF-D, and VEGFR-3 and their roles in lymphatic metastasis of tumors

The Vascular Endothelial Growth Factor Family and Antiangiogesis Therapy

VEGF Signal System: the Application of Antiangiogenesis.

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

VEGF-D and the Lymphatic Metastasis of Malignancy

Role of Lymphangiogenic Factors in Tumor Metastasis

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance.

Vascular Endothelial Growth Factor in Breast Cancer： A Systematic Review

Anti-cancer drugs targeting vascular endothelial growth factors and receptors:research advances

Progression of VEGF-targeted cancer therapy

Advances in tumor vascular growth inhibition

Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance

Direct and indirect regulation of the tumor immune microenvironment by VEGF

VEGF-B Promotes Cancer Metastasis Through a VEGF-A–independent Mechanism and Serves As a Marker of Poor Prognosis for Cancer Patients